Item 1.01 Entry into a Material Definitive Agreement.

On March 19, 2021, our Chief Executive Officer, Mr. Kingrich Lee executed a Deed of Gift to irrevocably and unconditionally give, transfer and assign, by way of gift, without limitation or restriction, to Luckwel Pharmaceuticals, Inc. (the "Company") all of his right, title and interest in, arising from and to the following drug programs:





  Program Code   Description

  KL-2118        Candidate drug to be developed into orally disintegrating tablets
                 (ODT) to treat Type 2 diabetes.

  KL-2119        Candidate drug to be developed into an oral formulation treatment
                 of HIV

  KL-2120        Candidate drug to be developed into a liquid injection for the
                 treatment of rheumatoid arthritis.

The foregoing description of the Deed of Gift does not purport to be complete and is qualified in its entirety by reference to the Deed of Gift, which is attached to this Current Report on Form 8-K as Exhibit 10.1.

© Edgar Online, source Glimpses